Product Information
AVANAFIL 200 MG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $49.9974 per EA under NDC 31722044230. Its NADAC has been published 37 times since Jan 21, 2026.
FDA first approved this application on Jun 14, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722044230
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AVANAFILApproval Type
Generic (ANDA)
FDA Application
ANDA209266FDA Approved
6/14/2024
TE Code
AB
On Market Since
6/14/2024
Pharmacological Classes
Price Statistics
The NADAC for AVANAFIL 200 MG TABLET has been published 37 times since Jan 21, 2026, and over the history we have for it it has risen 21.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.9974 per EA |
|---|---|
| All-time high | $49.9974 (Sep 30, 2026) |
| All-time low | $41.0315 (Jan 21, 2026) |
| 52-week high | $49.9974 |
| 52-week low | $41.0315 |
| Median price | $47.4663 |
| Average price | $45.8508 |
| Largest weekly change | +6.3% (Apr 22, 2026) |
| Weeks tracked | 37 |
| Tracking since | Jan 21, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Avanafil market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Avanafil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 5 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AVANAFIL 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AVANAFIL 200 MG TABLET, manufactured by Camber Pharmaceuticals Inc., is $49.9974 per EA (NDC 31722044230), effective Sep 30, 2026.
How has the price of AVANAFIL 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for AVANAFIL 200 MG TABLET has risen 21.9%. It has been tracked across 37 weekly CMS publications since Jan 21, 2026.
What are the highest and lowest recorded NADAC prices for AVANAFIL 200 MG TABLET?
Since Jan 21, 2026, the NADAC for AVANAFIL 200 MG TABLET has ranged from a low of $41.0315 (Jan 21, 2026) to a high of $49.9974 (Sep 30, 2026), with a median of $47.4663 per EA.
Are there cheaper alternatives to AVANAFIL 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of AVANAFIL 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AVANAFIL 200 MG TABLET?
AVANAFIL 200 MG TABLET (NDC 31722044230) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.